Agarwal Anubha, Huffman Mark D
Department of Medicine and Global Health Center, Washington University in St. Louis, St. Louis, MO, US.
The George Institute for Global Health, University of New South Wales, Sydney, AU.
Glob Heart. 2024 Feb 26;19(1):24. doi: 10.5334/gh.1310. eCollection 2024.
This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization's endorsement of polypills is essential for improving global access, particularly in low- and middle-income countries. The greatest health gains are expected in a primary prevention population which has a significantly higher burden of fatal and non-fatal cardiovascular disease compared with the population of individuals with prevalent cardiovascular disease. A focus on adoption, implementation, sustainment, and scale-up of polypills for prevention of cardiovascular disease is needed including increasing supply of available polypills and incorporating polypills into the World Health Organization HEARTS technical package for integration into primary care systems to realize these benefits for population health. Widespread implementation of polypills for prevention of cardiovascular disease has the potential to equitably reduce the impact of cardiovascular disease globally by simplifying treatment options and expanding accessibility across economic levels, both across and within countries.
本评论阐述了将复方制剂纳入《世界卫生组织基本药物标准清单》第23版以预防心血管疾病的潜在影响，并提供了采用、实施、维持和扩大使用复方制剂的路线图。世界卫生组织对复方制剂的认可对于改善全球可及性至关重要，尤其是在低收入和中等收入国家。预计在初级预防人群中能获得最大的健康收益，与患有心血管疾病的人群相比，该人群致命和非致命心血管疾病的负担要高得多。需要关注复方制剂在预防心血管疾病方面的采用、实施、维持和扩大使用问题，包括增加复方制剂的供应，并将复方制剂纳入世界卫生组织“HEARTS”技术包，以便整合到初级保健系统中，从而为人群健康实现这些益处。广泛实施复方制剂预防心血管疾病有可能通过简化治疗选择并在国家间和国家内扩大不同经济水平人群的可及性，公平地减少心血管疾病在全球的影响。
